SG Americas Securities LLC Sells 145 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Share on StockTwits

SG Americas Securities LLC lessened its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 7.1% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,901 shares of the medical research company’s stock after selling 145 shares during the quarter. SG Americas Securities LLC’s holdings in Bio-Rad Laboratories were worth $858,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. State Street Corp increased its holdings in Bio-Rad Laboratories by 4.5% in the 1st quarter. State Street Corp now owns 686,687 shares of the medical research company’s stock valued at $240,725,000 after buying an additional 29,834 shares during the period. AQR Capital Management LLC increased its holdings in Bio-Rad Laboratories by 20.7% in the 1st quarter. AQR Capital Management LLC now owns 386,102 shares of the medical research company’s stock valued at $134,626,000 after buying an additional 66,260 shares during the period. Alliancebernstein L.P. increased its holdings in Bio-Rad Laboratories by 1.6% in the 1st quarter. Alliancebernstein L.P. now owns 384,481 shares of the medical research company’s stock valued at $134,784,000 after buying an additional 6,148 shares during the period. Artemis Investment Management LLP increased its holdings in Bio-Rad Laboratories by 129.8% in the 1st quarter. Artemis Investment Management LLP now owns 258,641 shares of the medical research company’s stock valued at $89,864,000 after buying an additional 146,088 shares during the period. Finally, Geode Capital Management LLC grew its holdings in shares of Bio-Rad Laboratories by 2.4% in the 1st quarter. Geode Capital Management LLC now owns 248,937 shares of the medical research company’s stock worth $87,193,000 after purchasing an additional 5,951 shares during the last quarter. 62.89% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NYSE:BIO opened at $524.89 on Friday. Bio-Rad Laboratories, Inc. has a 12 month low of $307.39 and a 12 month high of $540.06. The company’s 50-day moving average price is $474.38 and its two-hundred day moving average price is $419.24. The company has a quick ratio of 1.76, a current ratio of 2.40 and a debt-to-equity ratio of 0.03. The firm has a market cap of $15.56 billion, a P/E ratio of 8.14 and a beta of 1.08.

Bio-Rad Laboratories (NYSE:BIO) last issued its quarterly earnings data on Thursday, July 30th. The medical research company reported $1.61 EPS for the quarter, topping analysts’ consensus estimates of $1.22 by $0.39. Bio-Rad Laboratories had a net margin of 84.89% and a return on equity of 3.92%. The firm had revenue of $536.88 million for the quarter, compared to analyst estimates of $526.80 million. As a group, equities analysts predict that Bio-Rad Laboratories, Inc. will post 7.2 earnings per share for the current fiscal year.

In other Bio-Rad Laboratories news, VP Ronald W. Hutton sold 443 shares of the company’s stock in a transaction dated Wednesday, May 13th. The shares were sold at an average price of $457.35, for a total transaction of $202,606.05. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Michael Crowley sold 1,500 shares of the company’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $485.40, for a total transaction of $728,100.00. Following the transaction, the executive vice president now owns 2,310 shares in the company, valued at $1,121,274. The disclosure for this sale can be found here. 27.50% of the stock is owned by corporate insiders.

BIO has been the topic of several analyst reports. Wells Fargo & Co upped their target price on shares of Bio-Rad Laboratories from $525.00 to $590.00 and gave the stock an “overweight” rating in a report on Friday. Citigroup upped their target price on shares of Bio-Rad Laboratories from $525.00 to $625.00 and gave the stock a “buy” rating in a report on Friday. One analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $511.25.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components.

Read More: Shanghai Stock Exchange Composite Index

Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO).

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Berkshire Hills Bancorp  Stock Rating Upgraded by DA Davidson
Berkshire Hills Bancorp Stock Rating Upgraded by DA Davidson
Builders FirstSource  PT Raised to $31.00
Builders FirstSource PT Raised to $31.00
UBS Group  Rating Increased to Sell at ValuEngine
UBS Group Rating Increased to Sell at ValuEngine
Boeing Co Forecasted to Earn FY2023 Earnings of $11.75 Per Share
Boeing Co Forecasted to Earn FY2023 Earnings of $11.75 Per Share
KDDI CORP/ADR  Forecasted to Post FY2023 Earnings of $1.44 Per Share
KDDI CORP/ADR Forecasted to Post FY2023 Earnings of $1.44 Per Share
NCR  Receives Daily News Sentiment Score of -1.20
NCR Receives Daily News Sentiment Score of -1.20


© 2006-2020 Ticker Report